Patents Assigned to Tasuku Honjo
-
Patent number: 9393301Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1 PD-L2 are useful for cancer or infection treatment.Type: GrantFiled: January 19, 2016Date of Patent: July 19, 2016Assignees: ONO PHARMACEUTICAL CO., LTD., TASUKU HONJOInventors: Tasuku Honjo, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Publication number: 20150197572Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.Type: ApplicationFiled: March 4, 2015Publication date: July 16, 2015Applicants: Ono Pharmaceutical Co., LTD., Tasuku HONJOInventors: Tasuku HONJO, Nagahiro MINATO, Yoshiko IWAI, Shiro SHIBAYAMA
-
Publication number: 20150118234Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: ApplicationFiled: December 29, 2014Publication date: April 30, 2015Applicants: TASUKU HONJO, ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku HONJO, Shiro SHIBAYAMA, Kazuhiko TAKEDA, Masayoshi MATSUO, Takao YOSHIDA, Masakazu MIYAMOTO
-
Patent number: 8246955Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: GrantFiled: June 27, 2011Date of Patent: August 21, 2012Assignees: Ono Pharmaceutical Co., Ltd., Tasuku HonjoInventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
-
Publication number: 20110081341Abstract: Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.Type: ApplicationFiled: December 2, 2010Publication date: April 7, 2011Applicants: ONO PHARMACEUTICAL CO., LTD., Tasuku HONJOInventors: Tasuku HONJO, Nagahiro Minato, Yoshiko Iwai, Shiro Shibayama
-
Publication number: 20090263865Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.Type: ApplicationFiled: May 20, 2009Publication date: October 22, 2009Applicants: Tasuku HONJO, ONO PHARMACEUTICAL CO., LTD.Inventors: Tasuku HONJO, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
-
Patent number: 5698520Abstract: A membrane protein related to human programmed cell death (PD-1) and DNA encoding the said protein is provided. PD-1 protein may be useful for the treatment of various infections, immunological depression or acceleration, or tumors etc.Type: GrantFiled: December 18, 1996Date of Patent: December 16, 1997Assignees: Ono Pharmaceutical Co., Ltd., Tasuku HonjoInventors: Tasuku Honjo, Yasumasa Ishida, Takashi Shinohara
-
Patent number: 5629204Abstract: A membrane protein related to human programmed cell death (PD-1) and DNA encoding the said protein is provided. PD-1 protein may be useful for the treatment of various infections, immunological depression or acceleration, or tumors etc.Type: GrantFiled: March 1, 1995Date of Patent: May 13, 1997Assignees: Ono Pharmaceutical Co., Ltd., Tasuku HonjoInventors: Tasuku Honjo, Yasumasa Ishida, Takashi Shinohara
-
Patent number: 5525486Abstract: The present invention relates to (1) a process for constructing a cDNA library which has a selectivity for signal peptides, that makes it possible to efficiently find out an unknown and useful polypeptide and a high efficiency; and relates to (2) a novel polypeptide consisting of 89 amino acids (including a signal peptide) produced by a stroma cell line, which is useful as an agent for preventing or treating, for example, anemia, leukopenia or infections and the like, and DNAs encoding for said polypeptide.Type: GrantFiled: January 14, 1994Date of Patent: June 11, 1996Assignees: Tasuku Honjo, Ono Pharmaceutical Co., Ltd.Inventors: Tasuku Honjo, Kei Tashiro, Hideaki Tada
-
Patent number: 5416201Abstract: Mouse IgG.sub.1 inducing factor and the DNA that codes for the same were isolated by using a novel genetic technique, and their structures determined by the dideoxy chain termination method. The mouse IgG.sub.1 inducing factor obtained by the method of this invention has activity to improve immune response in living bodies and are hence useful for the treatment and prevention of infectious diseases, AIDS, functional immunodeficiency and the like. This factor, or part of its amino acid sequence, may also be used for the preparation of antibody against the same. In addition, it is possible to use this factor as a model for the synthesis of other polypeptides having similar structures, and for many other purposes.Type: GrantFiled: September 30, 1986Date of Patent: May 16, 1995Assignee: Tasuku HonjoInventors: Tasuku Honjo, Eva Severinson
-
Patent number: 4816565Abstract: Interleukin 2 receptor protein having the following properties:(a) molecular weight: 40 to 43 kd,(b) pI of 5.2 to 4.Type: GrantFiled: August 11, 1986Date of Patent: March 28, 1989Assignee: Tasuku HonjoInventors: Tasuku Honjo, Akira Shimizu